Zevra Therapeutics: Strong Buy Rating Backed by Impressive Sales and Robust Financial Position

Oren Livnat, an analyst from H.C. Wainwright, reiterated the Buy rating on Zevra Therapeutics (ZVRA – Research Report). The associated price target is $20.00.

Oren Livnat has given his Buy rating due to a combination of factors surrounding Zevra Therapeutics’ recent performance and future potential. The company reported impressive initial sales of MIPLYFFA for Niemann-Pick type C, exceeding expectations significantly. The rapid enrollment of patients, particularly from the Expanded Access Program, highlights strong demand and effective execution by the company.
Furthermore, Zevra’s financial position is robust, with substantial cash reserves bolstered by a recent PRV sale. The company’s plans to expand into the European market and potential future developments in treatments for other conditions also contribute to the positive outlook. Despite some conservative adjustments to patient growth estimates, the overall potential for peak sales remains strong, supporting the Buy rating.

In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $18.00 price target.